Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) is now available.
JW (Cayman) Therapeutics Co. Ltd. has announced an amendment to its collaboration agreement with Regeneron, initially established with 2seventy bio, for the development of the MAGE-A4 Product for oncology in Greater China. The amendment includes Regeneron funding certain development activities and making milestone payments to JW Cayman, while also granting Regeneron a non-exclusive license for the Drug Product Process, which allows Regeneron to exploit its products globally, excluding the MAGE-A4 Product in the JW Territory. This strategic move is expected to bolster JW Cayman’s operational capabilities and strengthen its position in the oncology market.
The most recent analyst rating on (HK:2126) stock is a Sell with a HK$3.50 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd. is a biotechnology company focused on developing and commercializing innovative cell therapies for oncology indications, particularly in Greater China. The company engages in strategic alliances to enhance its product offerings and market reach.
Average Trading Volume: 3,671,080
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.5B
Find detailed analytics on 2126 stock on TipRanks’ Stock Analysis page.